Plasma levels of danger-associated molecular patterns are associated with immune suppression in trauma patients by Timmermans, K. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/171199
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Intensive Care Med (2016) 42:551–561
DOI 10.1007/s00134-015-4205-3
ORIGINAL
Plasma levels of danger-associated 
molecular patterns are associated with immune 
suppression in trauma patients
Kim Timmermans1,2, Matthijs Kox1,2, Michiel Vaneker2,3, Maarten van den Berg1, Aaron John1,2, 
Arjan van Laarhoven4, Hans van der Hoeven1, Gert Jan Scheffer2* and Peter Pickkers1*
 © 2016 The Author(s). This article is published with open access at Springerlink.com
Abstract 
Purpose: Danger-associated molecular patterns (DAMPs) released of trauma could contribute to an immune sup-
pressed state that renders patients vulnerable towards nosocomial infections. We investigated DAMP release in 
trauma patients, starting in the prehospital phase, and assessed its relationship with immune suppression and noso-
comial infections.
Methods: Blood was obtained from 166 adult trauma patients at the trauma scene, emergency room (ER), and seri-
ally afterwards. Circulating levels of DAMPs and cytokines were determined. Immune suppression was investigated by 
determination of HLA-DRA gene expression and ex vivo lipopolysaccharide-stimulated cytokine production.
Results: Compared with healthy controls, plasma levels of nuclear DNA (nDNA) and heat shock protein-70 (HSP70) 
but not mitochondrial DNA were profoundly increased immediately following trauma and remained elevated for 
10 days. Plasma cytokines were increased at the ER, and levels of anti-inflammatory IL-10 but not of pro-inflammatory 
cytokines peaked at this early time-point. HLA-DRA expression was attenuated directly after trauma and did not 
recover during the follow-up period. Plasma nDNA (r = −0.24, p = 0.006) and HSP70 (r = −0.38, p < 0.0001) levels 
correlated negatively with HLA-DRA expression. Ex vivo cytokine production revealed an anti-inflammatory pheno-
type already at the trauma scene which persisted in the following days, characterized by attenuated TNF-α and IL-6, 
and increased IL-10 production. Finally, higher concentrations of nDNA and a further decrease of HLA-DRA expression 
were associated with infections.
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Take-home message: Plasma levels of DAMPs are associated with 
immune suppression, which is apparent within minutes/hours of trauma. 
Furthermore, aggravated immune suppression during the initial phase 
following trauma is associated with increased susceptibility towards 
infections.
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Introduction
The survival of multiple trauma patients has improved 
significantly during the past decades [1]. However, 
despite improvements in both traffic safety and pre- 
and in-hospital management, severe trauma remains 
a main cause of death among young people worldwide 
[2]. In 2014, 25,845 people were killed and over 203,500 
seriously injured in road accidents in the EU alone [3]. 
Roughly, trauma-related mortality can be divided into 
two categories. Early deaths are mainly attributed to neu-
rological damage or severe blood loss directly related to 
the trauma. The patients that survive the initial trauma 
often develop nosocomial infections or sepsis [4], rep-
resenting a significant cause of late mortality in trauma 
patients. The increased susceptibility of trauma patients 
to develop infections is mediated by a suppressed state 
of the immune system that develops after trauma [4–9]. 
Two frequently used hallmarks of the immune-sup-
pressed state after trauma are attenuated production of 
cytokines by leukocytes ex  vivo stimulated with path-
ogen-associated molecular patterns (PAMPs) such as 
lipopolysaccharide (LPS), and decreased leukocyte HLA-
DR expression [6, 8, 10–13].
Release of danger-associated molecular patterns 
(DAMPs), which can elicit an immune response very 
similar to the response to PAMPs from invading patho-
gens in sepsis [14, 15], could contribute to immune sup-
pression in trauma patients. DAMPs can both be actively 
released by ischemic cells as danger signals or origi-
nate from damaged or dead cells as debris [16, 17]. An 
example of a DAMP that can be released in the case of 
cell damage is mitochondrial DNA (mtDNA), which can 
trigger an immune response via Toll-like receptor 9 [18, 
19]. Moreover, heat shock protein (HSP)-70 is released 
following trauma [20] and has been shown to induce 
immune cell deactivation [21]. Furthermore, previous 
studies have indicated that free nuclear DNA (nDNA) in 
plasma is a marker for cell damage or death, because it is 
one of the many cell components released if a cell is rup-
tured [19, 22]. Therefore, it might be an indicator of gen-
eral DAMP release. However, the role of these DAMPs 
in the immune response after trauma and the possible 
development of a suppressed state of the immune system 
is unknown.
Taken together, although immune suppression 
and nosocomial infections are frequently described 
phenomena in trauma patients, the role of DAMPs 
that trigger pro- and anti-inflammatory responses 
remains elusive. The aim of this study was to investi-
gate the release of DAMPs following trauma, starting 
in the very early (prehospital) phase, and to assess its 
relationship with immune suppression and nosocomial 
infections.
Parts of this work were presented at the 33rd Inter-
national Symposium on Intensive Care and Emergency 
Medicine, held on 19–22 March 2013 in Brussels, Bel-
gium [23] and at the European Society of Intensive Care 
Medicine (ESICM) Lives Annual Congress, held on 27 
September–1 October 2014 in Barcelona, Spain [24].
Methods
Study population
Adult trauma patients (n = 166) admitted to the trauma 
care unit at the emergency room (ER) of the Radboud 
University Nijmegen Medical Centre were included in 
the study. Exclusion criteria were expected risk of blood 
sampling at the trauma scene (e.g., jeopardizing the clini-
cal handling of the patient), known HIV/AIDS, known 
malignancies, and use of steroids (all dosages and types of 
administration) or other immunomodulatory medication 
previously to the trauma. Selective digestive tract decon-
tamination (SDD) was administered to all patients who 
were admitted to the ICU (n  =  101), as part of stand-
ard ICU protocol. Therefore, comparisons between ICU 
patients who did and did not receive antibiotics could not 
be made. Of the patients who were not admitted to the 
ICU (n = 65), only seven received (prophylactic) antibi-
otics; this group size does not allow for statistical analy-
sis. Furthermore, comparing patients that did not receive 
antibiotics (and thus by definition were not admitted 
to the ICU) with patients that did receive antibiotics 
(all ICU patients and the seven non-ICU patients that 
received antibiotics) does not yield meaningful infor-
mation, because of major differences in trauma/disease 
severity, placement of catheters, intubation etc.
The study was carried out in the Netherlands in accord-
ance with the applicable rules concerning the review 
of research ethics committees and informed consent 
(CMO2011/380, NL38169.091.11). All patients or legal 
representatives were informed about the study details at 
the first opportunity, usually within 1  day after admis-
sion. The local ethical committee that approved the study 
Conclusions: Plasma levels of DAMPs are associated with immune suppression, which is apparent within minutes/
hours following trauma. Furthermore, aggravated immune suppression during the initial phase following trauma is 
associated with increased susceptibility towards infections.
Keywords: Trauma, Injury, Immune suppression, DAMPs, Infection
Page 553 of 561
protocol agreed that it was not possible to do this at an 
earlier stage. Written informed consent was obtained 
from the patient or his/her legal representative if vena 
puncture was necessary to obtain blood samples. All 
determinations and data handing were performed under 
the guidelines of The National Institutes of Health and in 
accordance with the declaration of Helsinki and its later 
amendments.
Control samples (n = 12) were obtained from healthy 
male volunteers (median age 22 [interquartile range 
19–27]  years) participating in an experimental human 
endotoxemia trial (CMO2012/455, NCT01835457). Sam-
ples were obtained from the control group at baseline, 
before administration of endotoxin. Written informed 
consent was obtained from all of these volunteers prior 
to screening and inclusion in the study.
Sample and data collection
Blood was sampled shortly after trauma at the trauma 
scene by the Helicopter Emergency Medical Services 
(HEMS) before hospital admission (“pre-hospital”) if 
applicable, at arrival at the ER, and at days 1, 3, 5, 7, and 
10 following trauma. The HEMS response time (time 
between notification of the HEMS team and arrival at 
the trauma scene) was 16 [12–19] min. Time spent at the 
trauma scene by the HEMS team was 23 [15–29]  min 
and the interval between sampling at the trauma scene 
(time-point HEMS) and sampling at the ER was 39 
[33–45] min.
Lithium heparin (LH) anti-coagulated blood was 
obtained for ex  vivo stimulation experiments as 
described below, which were performed immediately 
after sampling. Ethylenediaminetetraacetic acid (EDTA) 
and LH anti-coagulated blood was centrifuged after with-
drawal at 1600×g at 4 °C for 10 min, after which plasma 
was stored at −80 °C until further analysis. EDTA plasma 
for real-time quantitative PCR (qPCR) analysis was cen-
trifuged again at 16,000×g at 4 °C for 10 min to remove 
potential remaining cells and cell debris. The superna-
tant was stored at −80  °C until further analysis. Blood 
for mRNA analysis was sampled in PAXgene blood RNA 
tubes (Qiagen, Valencia, CA, USA) and stored according 
to the manufacturer’s instructions.
Clinical parameters and demographic data were 
obtained from electronic patient files. Injury sever-
ity scores (ISS) were supplied by the Regional Emer-
gency Healthcare Network. Infection within 28 days was 
defined as the presence of fever and/or other infectious 
symptoms (pain, swelling, erythema) with leukocytosis 
and positive cultures and/or another visible or otherwise 
proven infection focus corresponding to the symptoms 
of the patient. The attending physicians were blinded to 
the immune investigation results as these assays were 
performed after collection of all samples from each 
patient.
Plasma DAMP levels
Plasma from doubly centrifuged EDTA anti-coagulated 
blood was diluted 1:1 with phosphate buffered saline 
solution (PBS) after which DNA was isolated using 
the QIAamp DNA Blood Midi Kit (Qiagen, Valencia, 
CA, USA), using the “Spin Protocol” as described by 
the manufacturer. Isolated DNA was stored at −20  °C 
until further analysis. qPCR was performed using 
iQ SYBR Green PCR Master Mix (Bio-Rad Labora-
tories, Hercules, CA, USA) on a CFX96 Real-Time 
PCR Detection System (Bio-Rad Laboratories, Hercu-
les, CA, USA). A primer pair specific for the GAPDH 
gene present in all nucleated cells of the body was 
used for quantification of nuclear (n)DNA levels: for-
ward 5′-AGCACCCCTGGCCAAGGTCA-3′, reverse 
5-CGGCAGGGAGGAGCCAGTCT-3′. For quantifi-
cation of mitochondrial (mt)DNA levels, the following 
primer pair specific for the mitochondrially encoded 
NADH dehydrogenase  1 (MT-ND1) gene was used: 
forward 5′-GCCCCAACGTTGTAGGCCCC-3′ and 
reverse 5′AGCTAAGGTCGGGGCGGTGA-3′. Primer 
pairs were obtained from Biolegio (Nijmegen, the Neth-
erlands). Samples were analyzed in duplicate and DNA 
isolated from blood obtained from a healthy volunteer 
was used on each plate as a calibrator [CV  % of 1.48  % 
(GAPDH) and 0.41 % (mtDNA) between plates]. Plasma 
nDNA and mtDNA levels are expressed as fold change 
relative to the calibrator sample using the formula 2ΔCt.
Plasma concentrations of HSP70/HSPA1A were deter-
mined batchwise using ELISA according to the manu-
facturer’s instructions (R&D systems, Minneapolis, MN, 
USA).
Plasma cytokine concentrations
Plasma concentrations of the pro-inflammatory cytokines 
tumor necrosis factor (TNF)-α, interleukin (IL)-6, and 
IL-8, and the anti-inflammatory cytokine IL-10 were 
analyzed batchwise in plasma obtained from EDTA anti-
coagulated blood using a simultaneous Luminex assay 
according to the manufacturer’s instructions (Milliplex; 
Millipore, Billerica, MA, USA).
Ex vivo cytokine production
Leukocyte cytokine production capacity was determined 
by challenging whole blood from the patients with LPS 
ex vivo using an in-house developed system with prefilled 
tubes described in detail elsewhere [25]. Briefly, 0.5  mL 
of blood was added to tubes prefilled with 2 mL culture 
medium as negative control or 2  mL culture medium 
supplemented with 12.5  ng/mL Escherichia coli LPS 
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[serotype O55:B5 (Sigma Aldrich, St Louis, MO, USA), 
end concentration 10  ng/mL]. Cultures were incubated 
at 37  °C for 24  h, centrifuged, and supernatants were 
stored at −80 °C until analysis. Concentrations of TNF-
α, IL-6, and IL-10 were determined batchwise by ELISA 
according to the manufacturer’s instructions (R&D sys-
tems, Minneapolis, MN, USA). Ex vivo cytokine produc-
tion data were censored at time of infection diagnosis, 
because infections can induce immune alterations.
HLA‑DRA mRNA expression
RNA was isolated from blood collected in Paxgene blood 
RNA tubes (Qiagen, Valencia, CA, USA). cDNA was syn-
thesized from total RNA using the iScript cDNA Synthe-
sis Kit (Bio-rad, Hercules, CA, USA). Subsequent qPCR 
analysis was performed using TaqMan gene expression 
assays (Life Technologies, Paisley, UK) for the reference 
gene peptidylpropylisomerase  B (PPIB) (#Hs00168719_
m1) and HLA-DRA (#Hs00219575_m1) on a CFX96 
Real-Time PCR Detection System (Bio-Rad, Hercules, 
CA, USA). We chose PPIB on the basis of its stability in 
inflammatory conditions in peripheral whole blood [26] 
and previous use as a reference gene for HLA-DRA [27]. 
We chose the HLA-DRA gene because it was shown to 
correlate well with flow cytometric analysis of mHLA-DR 
[27–29], an established marker of immune suppression. 
HLA-DRA expression levels are expressed as fold change 
relative to the expression of PPIB in the same sample 
using the formula  2ΔCt. HLA-DRA data were censored 
at time of infection diagnosis, because infections can 
decrease HLA-DR expression.
Statistical analysis
Data presented in tables and text are expressed as median 
[interquartile range] and data in figures as geometric 
mean ± 95 % CI. Mann–Whitney U and Fischer exact tests 
were used to investigate differences between two groups 
as appropriate. Differences between patient data at the 
various time-points and data of healthy controls were per-
formed using Kruskal–Wallis with Dunn’s post hoc tests. 
Differences between time-to-infection curves were tested 
using log-rank (Mantel–Cox) tests. A Cox proportional 
hazard model was used to adjust the relationship between 
HLA-DRA expression and time-to-infection for the usual 
clinical confounders age and ISS [10]. Correlations were 
calculated using Spearman correlation. All analyses were 
performed with available data of the corresponding time-
points. As a result of missing values at certain time-points 
or patients that were lost to follow-up, patient numbers in 
the analyses vary. Principal component analysis (PCA) was 
performed to explore the expected covariation between 
multiple laboratory variables and their relationship with 
injury severity, thereby preventing the need to list all indi-
vidual correlations [30]. No imputation was used, as miss-
ing values were judged to be non-random, i.e., blood for 
[X] was sampled at day [Y] and could therefore not be 
obtained in patients who died early. Instead, a core data 
set of variables and patients without missing values was 
established. Measurements were log-transformed, mean-
subtracted, and z-score was calculated on which PCA was 
performed on the basis of the singular value distribution 
in a Python script. All other statistical analyses were per-
formed using SPSS statistics version 22 (IBM Corpora-
tion, Armonk, NY, USA) and Graphpad Prism version 5 
(Graphpad Software, La Jolla, USA). A p value of less than 
0.05 was considered statistically significant.
Results
Patient characteristics
A total of 166 patients were included between August 
2010 and May 2013, the characteristics of which are 
listed in Table 1. The majority of patients suffered from 
head/neck or chest injury.
Plasma DAMPs
Plasma nDNA levels were profoundly increased at pre-
hospital and ER time-points compared with healthy 
Table 1 Patient characteristics
Initial trauma survivors were defined as patients who survived the initial 7 days 
following trauma. Vasopressor therapy always consisted of noradrenaline. 
Corticosteroids included all types of administration. Blood products included 
erythrocytes, thrombocytes, and fresh frozen plasma
a Admitted to or used within 28 days after hospital admission
Total (n = 166)
Gender
 Male n = 123 (74 %)
 Female  n = 43 (26 %)
Age (years) 50 [31–67]
Injury severity score 26 [17–37]
 Head/neck injury (ISS region 1) n = 129, 78 %
 Face injury (ISS region 2) n = 47, 28 %
 Chest injury (ISS region 3) n = 96, 58 %
 Abdomen or pelvic contents injury (ISS region 4) n = 44, 27 %
 Extremities or pelvic girdle injury (ISS region 5) n = 78, 47 %
 External injury (ISS region 6) n = 77, 46 %
ICU admissiona n = 101 (61 %)
 Mechanical ventilationa n = 96 (95 %)
 Vasopressor therapya n = 35 (35 %)
 ICU length of stay (days) 3 [1–7]
Corticosteroids administereda n = 8 (5 %)
Transfusion of blood productsa n = 24 (14 %)
Hospital length of stay (days) 8 [1–17]
28-day survival n = 127 (77 %)
28-day survival (among initial trauma survivors) n = 127/147 (86 %)
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controls (Fig. 1a). Although levels decreased in the later 
phase, they remained elevated during the entire follow-
up period. Plasma mtDNA levels were also elevated in 
trauma patients compared with healthy controls (Fig. 1b), 
although this increase was not as pronounced and only 
reached statistical significance at two time-points. Simi-
lar to nDNA, plasma HSP70 concentrations in trauma 
patients were highest shortly after trauma and decreased 
later on, but nevertheless remained elevated compared 
with healthy controls at all time-points (Fig. 1c).
Plasma cytokines
Plasma TNF-α concentrations in trauma patients were 
not elevated at any time-point compared with levels 
found in healthy controls and did not change over time 
(Supplementary Fig. 1). Plasma IL-6 levels were elevated 
from time-point ER until day  7 post-trauma (Fig.  1d), 
while IL-8 levels were slightly but significantly increased 
compared with healthy controls from time-point ER and 
remained elevated during the entire follow-up period 
(Fig. 1e). Both cytokines showed highest levels at day 1. 
Plasma IL-10 concentrations in trauma patients showed a 
distinct peak at the ER and remained significantly higher 
compared with healthy controls until day  1 (Fig.  1f ). 
Plasma nDNA levels measured at the ER correlated with 
plasma IL-8 (r = 0.40, p < 0.0001, n = 121), IL-6 (r = 0.47, 
p  <  0.0001, n  =  121), and IL-10 (r  =  0.45, p  <  0.0001, 
n = 121) concentrations at the same time-point. Plasma 
HSP70 levels at the ER correlated with plasma IL-8 
(r = 0.40, p < 0.0001, n = 100), IL-6 (r = 0.45, p < 0.0001, 
n = 100), and IL-10 (r = 0.48, p < 0.0001, n = 100) levels 
at that time-point.
Immune‑suppressed state
HLA-DRA mRNA expression in trauma patients was 
profoundly suppressed at all time-points compared with 
healthy controls (Fig.  2a). Plasma nDNA and HSP70 
levels negatively correlated with HLA-DRA expres-
sion at time-point ER (r =  −0.24, p  =  0.006, n  =  130, 
and r = −0.38, p < 0.0001, n = 106, respectively), while 
plasma mtDNA levels did not correlate with HLA-DRA 
expression (r = −0.09, p = 0.33, n = 130).
Ex vivo cytokine production capacity was investigated 
in a subgroup of patients (n = 36), whose characteristics 
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were comparable to the entire patient cohort (supple-
mentary Table 1). The capacity of leukocytes to produce 
pro-inflammatory cytokines TNF-α and especially IL-6 
upon ex  vivo stimulation with LPS was severely sup-
pressed at the trauma scene and during the first days 
of hospital admission compared with healthy controls 
(Fig. 2b, c). In sharp contrast, ex vivo production of the 
anti-inflammatory cytokine IL-10 was augmented in the 
first days after trauma compared with healthy controls 
(Fig. 2d). This effect remained evident during the entire 
10-day follow-up period (data not shown). Ex vivo TNF-α 
and IL-6 production at the ER correlated positively with 
HLA-DRA expression (r =  0.43, p =  0.02, n =  30, and 
r =  0.58, p =  0.001, n =  30, respectively). This was not 
the case for ex vivo IL-10 production (r = 0.22, p = 0.25, 
n = 30).
Relationship between injury severity, DAMPs, cytokines, 
and HLA‑DRA
To comprehensively investigate the relationship between 
injury severity and the mediators measured, we PCA on 
data of nDNA, mtDNA, HSP70, IL-10, IL-6, IL-8, TNF-α, 
and HLA-DRA expression at the ER. In concordance 
with the individual correlations shown, the first prin-
cipal component (PC1) had high loadings in the same 
direction of plasma nDNA, HSP70, IL-10, IL-6, IL-8, and 
TNF-α levels, while HLA-DRA had a smaller negative 
loading. PC1 had a total explained variance of 46 % and 
correlated with ISS (r = 0.64 p < 0.0001, supplementary 
Figure  2).
Susceptibility towards infections
Thirty-three patients (20 %) developed an infection dur-
ing the first 28 days following trauma (characteristics of 
infected and non-infected patients provided in supple-
mentary Table 2, upper part). Time until infection was 7 
[4–12] days. Types of infection were pneumonia (n = 21), 
wound infection (n = 5), meningitis (n = 4), urinary tract 
infection (n  =  2), central line infection (n  =  1), empy-
ema (n = 1), bacteremia (n = 1), paronychia (n = 1), and 
unknown (n = 1). Four patients suffered from two infec-
tions. Eighteen out of 21 patients with pneumonia were 
intubated at hospital admission and 15 at the moment of 
pneumonia diagnosis. Gender, age, and injury severity 
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and injury location were comparable between patients 
who developed an infection within 28  days and those 
who did not. However, patients who developed an infec-
tion following trauma were more frequently admitted 
to the ICU, received more transfusions, and required a 
longer length of stay, both at the ICU and in the hospi-
tal. Furthermore, vasopressor therapy and corticosteroid 
use tended to be higher in patients who developed an 
infection. The 28-day survival was higher in patients who 
developed an infection compared with those who did 
not, likely due to direct trauma-related deaths. Indeed, 
when analyzing the data of patients who survived the 
initial phase after trauma, no difference in 28-day sur-
vival was observed (supplementary Table 2, lower part). 
ISS was slightly higher in patients who survived the ini-
tial phase after trauma and developed an infection, and 
these patients were more frequently admitted to the ICU. 
Furthermore, vasopressor therapy, transfusions, and cor-
ticosteroids were more frequently used, and ICU and 
hospital length of stay were increased in these patients.
Plasma mtDNA and nDNA levels at ER were higher 
in patients who developed an infection within 28  days 
compared with patients who did not (2.5 [1.4–6.6] vs. 1.4 
[0.5–4.0] fold change, p =  0.046 for mtDNA, and 265.7 
[30.7–1131.3] vs. 61.9 [11.7–367.5] fold change, p = 0.02 
for nDNA). For HSP70, no differences were observed 
between these two groups (57.4 [26.0–79.8] vs. 47.2 
[33.9–72.0] ng/mL, p = 0.89).
Previous studies indicate that the change in HLA-DR 
expression over time better predicts outcome and/or 
development of infections than absolute values of HLA-
DR [10, 29, 31]. Accordingly, we investigated the relation-
ship between change in HLA-DRA expression (increase 
or decrease between ER and day  3) and infections in a 
subgroup of patients from our cohort for which HLA-
DRA data was available on these time-points. Patients 
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in the release of DAMPs including, but not limited to, nDNA and 
HSP70. Subsequently, DAMPs bind to (intracellular) receptors on 
immune cells such as macrophages, which induces a predominantly 
anti-inflammatory response characterized by IL-10 release. In turn, 
this leads to immune suppression, indicated by decreased monocytic 
HLA-DR expression as well as reduced production of TNF-α/IL-6 and 
increased production of IL-10 upon ex vivo stimulation with LPS. 
Alternatively, DAMPs can exert direct immunosuppressive effects, 
such as HSP70-induced LPS tolerance in monocytes. All these events 
take place in the very early (prehospital) phase following trauma. 
In the hospital, aggravated immune suppression is associated with 
increased susceptibility towards infections, consequent prolonged 
ICU and hospital length-of-stay, and increased late mortality
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exhibiting a decrease in HLA-DRA expression (ratio 
<1) more likely developed an infection compared with 
patients who showed an increase (ratio >1, Fig.  3). The 
relationship between a decrease in HLA-DRA expression 
and development of infection remained apparent after 
correcting for age and ISS (hazard ratio [95 % CI] of 3.02 
[1.02–8.93], p =  0.046). Furthermore, ICU and hospital 
length of stay were increased in patients with decreasing 
HLA-DRA expression, while other characteristics were 
not significantly different (supplementary Table 3).
Discussion
This study demonstrates that multi-trauma patients 
exhibit a suppressed state of the immune system already 
at the trauma scene, thus before admission of the patient 
to the hospital. This is characterized by low HLA-DRA 
expression and an anti-inflammatory cytokine pattern, 
both in  vivo and ex  vivo. Furthermore, we show that 
DAMPs are present in large quantities in the circulation 
during the prehospital phase and shortly after admission, 
and that DAMP levels are associated with the extent of 
immune suppression. Finally, our data demonstrate that 
further aggravation of immune suppression in the initial 
phase after trauma is associated with increased suscep-
tibility towards infections. A conceptual representation 
of how DAMP release may lead to increased susceptibil-
ity towards infections following trauma is presented in 
Fig. 4.
The pronounced general release of DAMPs, reflected by 
plasma nDNA levels, in the prehospital phase of trauma 
was associated with the immune suppression observed in 
our cohort of trauma patients. Although an observational 
study such as the current does not allow one to draw con-
clusions concerning cause and effect, our data suggests 
that DAMPs play a role in the suppressed state of the 
immune system. There are some data in support of this. 
HSP70 is known to induce LPS tolerance in monocytes, 
an in  vitro phenomenon showing similarities to in  vivo 
immune suppression [21]. Accordingly, we found a 
inverse relation between plasma HSP70 levels and HLA-
DRA expression. Moreover, previous studies have sug-
gested an immunomodulatory role for mtDNA in trauma 
patients [18, 32]. Of interest, while levels of mtDNA were 
increased after trauma, this increase was relatively mod-
est. Levels of circulating nDNA were much higher and, 
unlike mtDNA, correlated with HLA-DRA expression, 
indicating that mtDNA release is not one of the major 
factors behind immune suppression in trauma patients. 
Previous studies that demonstrated much higher mtDNA 
concentrations in plasma had much smaller patient num-
bers (n = 15 [18] and n = 38 [32]) and used only a single 
1600g centrifugation step [18, 32]. Chiu et  al. demon-
strated that double centrifugation of plasma (at 1600g 
and 16,000g, as performed in our study) is necessary to 
remove residual cells, each containing thousands of cop-
ies of the mitochondrial genome, making the results from 
one-spin protocol studies less reliable [33]. One could 
argue that a difference in injury severity could explain 
the difference, as Zhang et al. included only patients with 
ISS >25 [18]. However, Lam et al. included a majority of 
patients with ISS <16 [32], making it unlikely that the 
lower injury severity in our study population (median ISS 
of 26) explains the lower levels of mtDNA found.
Our study further shows that the early immune response 
following trauma has a distinct anti-inflammatory pheno-
type. Plasma levels of the archetypal pro-inflammatory 
mediator TNF-α were not increased whatsoever and 
increases in other pro-inflammatory cytokines such as 
IL-8 and IL-6 were relatively modest and peaked at later 
time-points. In sharp contrast, the anti-inflammatory 
cytokine IL-10 was produced rapidly following trauma 
and already reached peak levels at arrival in the ER. Of 
interest, in a previous study, trauma patients that were 
considered “immunoparalytic” based on HLA-DR expres-
sion on alveolar macrophages displayed higher IL-10 
levels in BAL fluid [34]. IL-10 attenuates the immune 
response in several ways, e.g., through inhibition of the 
production of proinflammatory cytokines, such as TNF-α 
and IL-6 [35]. In our study, the initial IL-10 peak was fol-
lowed by a peak in IL-6, which reached highest levels at 
day  1 following trauma. IL-6 is most renowned for its 
pro-inflammatory properties, although in trauma it is 
suggested that continuous IL-6 release accounts for the 
upregulation of anti-inflammatory mediators, such as 
prostaglandin E2, IL-1 receptor antagonist, IL-10, and 
transforming growth factor (TGF)-β and thereby also 
exhibits anti-inflammatory properties [36, 37]. These find-
ings indicate that immune suppression sets in directly 
after the injury. The mechanisms initiating this immedi-
ate anti-inflammatory response remain to be elucidated, 
although these findings are in agreement with the cur-
rent paradigm of the immune response during sepsis. 
In sepsis, it is now generally accepted that, instead of a 
previously assumed biphasic inflammatory response, 
consisting of an initial pro-inflammatory response and a 
subsequent compensatory anti-inflammatory response, 
a simultaneously occurring pro- and anti-inflammatory 
response is present [38]. Others have shown that the 
production of pro-inflammatory cytokines by leukocytes 
ex vivo stimulated with LPS is severely attenuated follow-
ing trauma [11, 13]. Herein, we confirm these findings and 
demonstrate that the production of IL-10 is increased in 
these patients, with both phenomena already apparent at 
the trauma scene. This distinct anti-inflammatory pheno-
type ex vivo in the early phase following trauma corrobo-
rates our in vivo findings.
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In keeping with previous work, our data reveal that 
HLA-DRA expression is decreased following trauma 
[6, 8, 10, 12, 13]. We importantly extend these findings 
by showing that this event already takes place before 
hospital admission and that DAMPs are associated 
with this phenomenon. The increased IL-10 levels early 
on following trauma might play a role in the decreased 
HLA-DRA expression, as IL-10 is known to reduce mac-
rophage function. Furthermore, in accordance with an 
earlier study [13], we demonstrate that low HLA-DRA 
levels were associated with decreased production of pro-
inflammatory cytokines in response to ex  vivo stimula-
tion of leukocytes with LPS. Several studies on small 
cohorts of trauma patients have investigated the relation-
ship between HLA-DR expression and infectious compli-
cations [6, 8, 12, 13]. Some have found (trends towards) 
associations between low HLA-DR expression and 
infections [6, 13], while others have not [12]. One study 
showed that reduced expression of HLA-DR on alveo-
lar macrophages, but not on circulating leukocytes, was 
associated with nosocomial pneumonia [8]. However, 
concerning the relation to outcome and/or development 
of infections, studies in trauma patients, septic patients, 
and in a cohort of ICU patients with various conditions 
have revealed that recovery of HLA-DR, rather than 
absolute values, is important [10, 29, 31]. In keeping 
with this, we found that a further decrease of HLA-DRA 
expression between admission and day 3 predicts devel-
opment of infections. Taken together, these data suggest 
that aggravated immune suppression following the initial 
hit increases the risk of infection after trauma. Neverthe-
less, the anti-inflammatory phenotype present directly 
after trauma might also have beneficial effects through 
limiting excessive inflammation and thereby organ dam-
age. As such, whether this phenotype is solely detrimen-
tal or has homeostatic features as well remains to be 
determined.
Our study has several limitations. First, inherent to this 
type of study, a substantial number of patients were lost 
to follow-up, e.g., because of discharge from the hospi-
tal or transfer to another hospital (in most cases due to 
recovery), or death (although mortality was low in our 
cohort). Therefore, if alterations in parameters observed 
initially in patients improve in those who recover, this 
could be missed. However, this does not affect the main 
conclusions of the manuscript as these are based on data 
obtained at early time-points and/or data of a subgroup 
of patients with a follow-up of several days. Another 
weakness of the current work typical for the multi-
trauma patient population studied is the heterogeneity of 
the patients.
Second, the use of plasma nDNA levels as a marker of 
general DAMP release could be debated, as it is possible 
that specific DAMPs display other release or clearance 
patterns and do not necessarily follow plasma nDNA 
concentrations. Future studies focusing on the extensive 
range of DAMPs important in trauma could shed more 
light on this phenomenon and the importance of individ-
ual DAMPs in trauma.
Third, we used expression of the HLA-DRA gene in 
whole blood leukocytes as a marker of immune suppres-
sion, while most studies have used HLA-DR expression on 
the surface of monocytes determined using flow cytometry 
for this purpose. Flow cytometric analysis requires rapid 
analysis after sampling and the constant availability of a 
flow cytometer, which was not feasible in our setting, espe-
cially with regard to the samples obtained at the trauma 
scene. Nevertheless, the use of gene expression data is a 
limitation, as post-transcriptional effects can also affect 
HLA-DRA expression. Furthermore, next to monocytes, 
other cells present in whole blood may also express the 
HLA-DRA gene to various extents and/or may exhibit dif-
ferent kinetics of expression, although there is little known 
on this subject in the context of immune suppression. In 
several studies in septic patients, a population which is, 
similar to ours, highly heterogeneous and likely exhibiting 
profound changes in leukocyte counts and differentiation 
over time, HLA-DRA gene expression was not corrected 
for leukocyte counts/differentiation [27–29, 39]. Also, we 
do not have adequate data on daily leukocyte counts and 
differentiation in our cohort, as these were not regularly 
measured in the majority of patients. Nevertheless, the 
aforementioned studies in septic patients have shown that 
gene expression of HLA-DRA correlates well with flow 
cytometric analysis of mHLA-DR, with correlation coef-
ficients ranging from 0.74 to 0.84 [27–29]; however, in one 
of these, a more moderate but still highly significant cor-
relation coefficient of 0.53 was found [39]. Therefore, we 
feel qPCR analysis of HLA-DRA in our study is a reliable 
indicator of HLA-DR expression and immune suppres-
sion. Yet, we acknowledge that the lack of data on leuko-
cyte counts is a limitation, because, next to possible effects 
on HLA-DR gene expression data, lymphopenia also rep-
resents a hallmark of immune suppression.
Finally, our control group consisted of solely young 
male volunteers. Especially with regard to the phenom-
enon of immunosenescence [40], this could have biased 
our results. However, when we compared levels of 
DAMPs and immunological parameters across five age 
categories [<28 (n = 33), 28–42 (n = 33), 43–56 (n = 34), 
57–70 (n  =  32), and >70 (n  =  32)], or between males 
and females within our patient cohort, we found no dif-
ferences in any of the parameters at any of the measured 
time-points. Also, we did not assess the functionality of 
the adaptive immune system, e.g., using functional assays 
such as proliferation or cytokine release by T cells.
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In conclusion, we demonstrate that trauma results in 
release of DAMPs and that this is associated with an acute 
predominantly anti-inflammatory response and a suppressed 
state of the immune system. In trauma patients, these events 
take place already before hospital admission and the observed 
immune suppressed state is not preceded or accompanied by 
a pronounced pro-inflammatory phase. Aggravated immune 
suppression, as indicated by further decrease of HLA-DRA 
expression, is associated with the development of nosocomial 
infections in this patient population.
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